<DOC>
	<DOCNO>NCT01726439</DOCNO>
	<brief_summary>To compare effectiveness , real world practice set tier 2 city China , Entecavir ( ETV ) monotherapy Lamivudine ( LAM ) base therapy ( include LAM monotherapy , de novo LAM + Adefovir [ ADV ] combination , early add-on ADV ) among chronic hepatitis B ( CHB ) patient naive NUC enrollment study</brief_summary>
	<brief_title>Effectiveness Nucleos ( ) Ide Analogs ( NUC ) Therapy Among Naive CHB Patients China</brief_title>
	<detailed_description>Sampling Method : Consecutive patient sample Biospecimen Retention : Blood sample HBV viral load test along treatment period study</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B , Chronic</mesh_term>
	<criteria>CHB patient , CHB patient compensate cirrhosis , define current Chinese guideline Male female ≥ 18 year age Either Hepatitis B e antigen ( HBeAg ) positive negative Naïve NUC ( define previous exposure NUC treatment base patient selfreport ) Has compensate liver disease Patients compensate cirrhosis Patients consent participate study Local resident medical reimbursement coverage prefer Coinfected hepatitis C virus ( HCV ) CHB patient decompensated cirrhosis , liver failure , hepatocellular carcinoma , type malignancy screen phase CHB patient treat interferon therapy within 6 month immediately prior screen phase study CHB patient confirm pregnancy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>